Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 176

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines

Open access
Demento, Stacey L., Siefert, Alyssa L., Bandyopadhyay, Arunima, Sharp, Fiona A., Fahmy, Tarek M.·2011·Trends in Biotechnology
DOI 10.1016/j.tibtech.2011.02.004
Open this paper in CoChat — free account

Abstract

Vaccine development has progressed significantly and has moved from whole microorganisms to subunit vaccines that contain only their antigenic proteins. Subunit vaccines are often less immunogenic than whole pathogens; therefore, adjuvants must amplify the immune response, ideally establishing both innate and adaptive immunity. Incorporation of antigens into biomaterials, such as liposomes and polymers, can achieve a desired vaccine response. The physical properties of these platforms can be easily manipulated, thus allowing for controlled delivery of immunostimulatory factors and presentation of pathogen-associated molecular patterns (PAMPs) that are targeted to specific immune cells. Targeting antigen to immune cells via PAMP-modified biomaterials is a new strategy to control the subsequent development of immunity and, in turn, effective vaccination. Here, we review the recent advances in both immunology and biomaterial engineering that have brought particulate-based vaccines to reality.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.tibtech.2011.02.004

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 128

  1. Steinman, 2001, Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation, Mt. Sinai J. Med., N.Y., 68, 160
  2. Geijtenbeek, 2000, DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells, Cell, 100, 587, 10.1016/S0092-8674(00)80694-7 · DOI · Paper page
  3. Baylor, 2002, Aluminum salts in vaccines—US perspective, Vaccine, 20, S18, 10.1016/S0264-410X(02)00166-4 · DOI · Paper page
  4. Eisenbarth, 2008, Use and limitations of alum-based models of allergy, Clin. Exp. Allergy, 38, 1572, 10.1111/j.1365-2222.2008.03069.x · DOI
  5. Sharp, 2009, Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome, Proc. Natl. Acad. Sci. U.S.A., 106, 870, 10.1073/pnas.0804897106 · DOI · Paper page
  6. Kool, 2008, Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome, J. Immunol., 181, 3755, 10.4049/jimmunol.181.6.3755 · DOI · Paper page
  7. Allison, 1974, Liposomes as immunological adjuvants, Nature, 252, 252, 10.1038/252252a0 · DOI · Paper page
  8. Copland, 2005, Lipid based particulate formulations for the delivery of antigen, Immunol. Cell Biol., 83, 97, 10.1111/j.1440-1711.2005.01315.x · DOI
  9. Nakanishi, 1999, Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins, J. Control Release, 61, 233, 10.1016/S0168-3659(99)00097-8 · DOI
  10. Hansen, 1995, Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures, Biochim. Biophys. Acta, 1239, 133, 10.1016/0005-2736(95)00138-S · DOI · Paper page
  11. Nellore, 1992, Evaluation of biodegradable microspheres as vaccine adjuvant for hepatitis B surface antigen, J. Parenter. Sci. Technol., 46, 176
  12. Singh, 1997, Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine, Infect. Immun., 65, 1716, 10.1128/IAI.65.5.1716-1721.1997 · DOI
  13. Singh, 1992, Immunogenicity studies on diphtheria toxoid loaded biodegradable microspheres, Int. J. Pharm., 85, R5, 10.1016/0378-5173(92)90157-W · DOI
  14. Singh, 1998, Controlled release microparticles as a single dose diphtheria toxoid vaccine: immunogenicity in small animal models, Vaccine, 16, 346, 10.1016/S0264-410X(97)80912-7 · DOI
  15. Kipper, 2006, Single dose vaccine based on biodegradable polyanhydride microspheres can modulate immune response mechanism, J. Biomed. Mater. Res. A, 76, 798, 10.1002/jbm.a.30545 · DOI
  16. Tamayo, 2010, Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation, Clin. Vaccine Immunol., 17, 1356, 10.1128/CVI.00164-10 · DOI
  17. Zaman, 2010, Synthetic polyacrylate polymers as particulate intranasal vaccine delivery systems for the induction of mucosal immune response, Curr. Drug Deliv., 7, 118, 10.2174/156720110791011846 · doi:10.2174/156720110791011846
  18. Jiang, 2005, Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens, Adv. Drug Deliv. Rev., 57, 391, 10.1016/j.addr.2004.09.003 · DOI · Paper page
  19. Bramwell, 2005, Particulate delivery systems for biodefense subunit vaccines, Adv. Drug Deliv. Rev., 57, 1247, 10.1016/j.addr.2005.01.010 · DOI
  20. O’Hagan, 1991, Controlled release microparticles for vaccine development, Vaccine, 9, 768, 10.1016/0264-410X(91)90295-H · DOI
  21. Gupta, 2007, M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B, J. Drug Target, 15, 701, 10.1080/10611860701637982 · DOI · Paper page
  22. Sesardic, 2004, European union regulatory developments for new vaccine adjuvants and delivery systems, Vaccine, 22, 2452, 10.1016/j.vaccine.2003.11.071 · DOI
  23. Gupta, 1998, Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines, Adv. Drug Deliv. Rev., 32, 225, 10.1016/S0169-409X(98)00012-X · DOI · Paper page
  24. Fahmy, 2005, Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting, Biomaterials, 26, 5727, 10.1016/j.biomaterials.2005.02.025 · DOI · Paper page
  25. Senel, 2004, Potential applications of chitosan in veterinary medicine, Adv. Drug Deliv. Rev., 56, 1467, 10.1016/j.addr.2004.02.007 · DOI · Paper page
  26. van der Lubben, 2001, Chitosan and its derivatives in mucosal drug and vaccine delivery, Eur. J. Pharm. Sci., 14, 201, 10.1016/S0928-0987(01)00172-5 · DOI · Paper page
  27. Wee, 1998, Protein release from alginate matrices, Adv. Drug Deliv. Rev., 31, 267, 10.1016/S0169-409X(97)00124-5 · DOI · Paper page
  28. Gao, 2009, Preparation and controlled degradation of oxidized sodium alginate hydrogel, Polym. Degrad. Stab., 94, 1405, 10.1016/j.polymdegradstab.2009.05.011 · DOI · Paper page
  29. Kelso, 1993, Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin, J. Allergy Clin. Immunol., 91, 867, 10.1016/0091-6749(93)90344-F · DOI · Paper page
  30. Di Marco, 2010, Overview of the main methods used to combine proteins with nanosystems: absorption, bioconjugation, and encapsulation, Int. J. Nanomed., 5, 37
  31. Veronese, 1999, Bioconjugation in pharmaceutical chemistry, Farmaco, 54, 497, 10.1016/S0014-827X(99)00066-X · DOI · Paper page
  32. Nwe, 2009, Growing applications of “click chemistry” for bioconjugation in contemporary biomedical research, Cancer Biother. Radiopharm., 24, 289, 10.1089/cbr.2008.0626 · DOI · Paper page
  33. Chieppa, 2003, Cross-linking of the mannose receptor on monocyte-derived dendritic cells activates an anti-inflammatory immunosuppressive program, J. Immunol., 171, 4552, 10.4049/jimmunol.171.9.4552 · DOI · Paper page
  34. Ferwerda, 2010, The role of Toll-like receptors and C-type lectins for vaccination against Candida albicans, Vaccine, 28, 614, 10.1016/j.vaccine.2009.10.082 · DOI
  35. Nomura, 1994, Prediction of the coding sequences of unidentified human genes. I. The coding sequences of 40 new genes (KIAA0001-KIAA0040) deduced by analysis of randomly sampled cDNA clones from human immature myeloid cell line KG-1, DNA Res., 1, 27, 10.1093/dnares/1.1.27 · DOI · Paper page
  36. Poltorak, 1998, Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene, Science, 282, 2085, 10.1126/science.282.5396.2085 · DOI · Paper page
  37. Kawai, 2010, The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors, Nat. Immunol., 11, 373, 10.1038/ni.1863 · DOI · Paper page
  38. Kawai, 2009, The roles of TLRs, RLRs and NLRs in pathogen recognition, Int. Immunol., 21, 317, 10.1093/intimm/dxp017 · DOI · Paper page
  39. Kobe, 2001, The leucine-rich repeat as a protein recognition motif, Curr. Opin. Struct. Biol., 11, 725, 10.1016/S0959-440X(01)00266-4 · DOI · Paper page
  40. Bortoluci, 2010, Control of infection by pyroptosis and autophagy: role of TLR and NLR, Cell. Mol. Life Sci.: CMLS, 67, 1643, 10.1007/s00018-010-0335-5 · DOI
  41. Carty, 2006, The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling, Nat. Immunol., 7, 1074, 10.1038/ni1382 · DOI · Paper page
  42. O’Neill, 2010, Sensing and signaling in antiviral innate immunity, Curr. Biol., 20, R328, 10.1016/j.cub.2010.01.044 · DOI · Paper page
  43. Shimizu, 2007, Triacylated lipoproteins derived from Mycoplasma pneumoniae activate nuclear factor-kappaB through toll-like receptors 1 and 2, Immunology, 121, 473, 10.1111/j.1365-2567.2007.02594.x · doi:10.1111/j.1365-2567.2007.02594.x
  44. Takeuchi, 2002, Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins, J. Immunol., 169, 10, 10.4049/jimmunol.169.1.10 · DOI · Paper page
  45. Takeuchi, 2001, Discrimination of bacterial lipoproteins by Toll-like receptor 6, Int. Immunol., 13, 933, 10.1093/intimm/13.7.933 · DOI · Paper page
  46. Espuelas, 2005, Effect of synthetic lipopeptides formulated in liposomes on the maturation of human dendritic cells, Mol. Immunol., 42, 721, 10.1016/j.molimm.2004.09.022 · DOI
  47. Heuking, 2009, Toll-like receptor-2 agonist functionalized biopolymer for mucosal vaccination, Int. J. Pharm., 381, 97, 10.1016/j.ijpharm.2009.03.039 · doi:10.1016/j.ijpharm.2009.03.039
  48. Wischke, 2009, Poly(I:C) coated PLGA microparticles induce dendritic cell maturation, Int. J. Pharm., 365, 61, 10.1016/j.ijpharm.2008.08.039 · DOI
  49. Heffernan, 2009, The stimulation of CD8+ T cells by dendritic cells pulsed with polyketal microparticles containing ion-paired protein antigen and poly(inosinic acid)-poly(cytidylic acid), Biomaterials, 30, 910, 10.1016/j.biomaterials.2008.10.034 · DOI
  50. Zaks, 2006, Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes, J. Immunol., 176, 7335, 10.4049/jimmunol.176.12.7335 · DOI · Paper page
  51. Kariko, 2004, Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3, J. Immunol., 172, 6545, 10.4049/jimmunol.172.11.6545 · DOI · Paper page
  52. Krieg, 2007, The toll of too much TLR7, Immunity, 27, 695, 10.1016/j.immuni.2007.11.001 · DOI
  53. Bekeredjian-Ding, 2006, T cell-independent, TLR-induced IL-12p70 production in primary human monocytes, J. Immunol., 176, 7438, 10.4049/jimmunol.176.12.7438 · DOI
  54. Hornung, 2002, Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides, J. Immunol., 168, 4531, 10.4049/jimmunol.168.9.4531 · DOI · Paper page
  55. Myschik, 2008, Immunogenicity of lipid sustained release implants containing imiquimod, alpha-galactosylceramide, or Quil-A, Pharmazie, 63, 686
  56. Johnston, 2007, TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines, Cancer Immunol. Immunother., 56, 1133, 10.1007/s00262-006-0262-3 · DOI
  57. Slade, 1998, Imiquimod 5% cream (Aldara), Expert Opin. Investig. Drugs, 7, 437, 10.1517/13543784.7.3.437 · doi:10.1517/13543784.7.3.437
  58. Akhtar, 1991, Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes), Nucleic Acids Res., 19, 5551, 10.1093/nar/19.20.5551 · DOI
  59. Gursel, 1999, Immunoadjuvant action of plasmid DNA in liposomes, Vaccine, 17, 1376, 10.1016/S0264-410X(98)00383-1 · DOI
  60. Gursel, 2001, Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides, J. Immunol., 167, 3324, 10.4049/jimmunol.167.6.3324 · DOI · Paper page
  61. Li, 2001, Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes, Vaccine, 20, 148, 10.1016/S0264-410X(01)00277-8 · DOI
  62. Joseph, 2002, Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines, Vaccine, 20, 3342, 10.1016/S0264-410X(02)00295-5 · DOI
  63. Singh, 2001, Cationic microparticles are an effective delivery system for immune stimulatory cpG DNA, Pharm. Res., 18, 1476, 10.1023/A:1012269226066 · DOI
  64. Borges, 2008, Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles, Eur. J. Pharm. Biopharm., 69, 405, 10.1016/j.ejpb.2008.01.019 · DOI · Paper page
  65. Fischer, 2009, Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response, J. Drug Target., 17, 652, 10.1080/10611860903119656 · doi:10.1080/10611860903119656
  66. Zwiorek, 2008, Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides, Pharm. Res., 25, 551, 10.1007/s11095-007-9410-5 · DOI
  67. Demento, 2010, TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis, J. Immunol., 185, 2989, 10.4049/jimmunol.1000768 · DOI
  68. Petrov, 1994, Non-specific modulation of the immune response with liposomal meningococcal lipopolysaccharide: role of different cells and cytokines, Vaccine, 12, 1064, 10.1016/0264-410X(94)90174-0 · DOI
  69. Jain, 2008, Enhancement of T-helper type I immune responses against hepatitis B surface antigen by LPS derivatives adjuvanted liposomes delivery system, J. Drug Target, 16, 706, 10.1080/10611860802295607 · doi:10.1080/10611860802295607
  70. Arigita, 2005, Well-defined and potent liposomal meningococcal B vaccines adjuvated with LPS derivatives, Vaccine, 23, 5091, 10.1016/j.vaccine.2005.06.001 · doi:10.1016/j.vaccine.2005.06.001
  71. Petrov, 1992, Toxicity and immunogenicity of Neisseria meningitidis lipopolysaccharide incorporated into liposomes, Infect. Immun., 60, 3897, 10.1128/IAI.60.9.3897-3903.1992 · DOI
  72. Franz, 1998, Adjuvant efficacy of gelatin particles and microparticles, Int. J. Pharm., 168, 153, 10.1016/S0378-5173(98)00069-6 · doi:10.1016/s0378-5173(98)00069-6
  73. Demento, 2009, Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy, Vaccine, 27, 3013, 10.1016/j.vaccine.2009.03.034 · DOI · Paper page
  74. Salkowski, 1997, Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages, Infect. Immun., 65, 3239, 10.1128/IAI.65.8.3239-3247.1997 · DOI
  75. Henricson, 1993, Dissociation of lipopolysaccharide (LPS)-inducible gene expression in murine macrophages pretreated with smooth LPS versus monophosphoryl lipid A, Infect. Immun., 61, 2325, 10.1128/IAI.61.6.2325-2333.1993 · DOI
  76. Elamanchili, 2007, Pathogen-mimicking” nanoparticles for vaccine delivery to dendritic cells, J. Immunother., 30, 378, 10.1097/CJI.0b013e31802cf3e3 · DOI
  77. Chong, 2005, Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery, J. Control Release, 102, 85, 10.1016/j.jconrel.2004.09.014 · DOI · Paper page
  78. Honko, 2005, Effects of flagellin on innate and adaptive immunity, Immunol. Res., 33, 83, 10.1385/IR:33:1:083 · DOI · Paper page
  79. Hayashi, 2001, The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5, Nature, 410, 1099, 10.1038/35074106 · DOI · Paper page
  80. Smith, 2003, Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility, Nat. Immunol., 4, 1247, 10.1038/ni1011 · DOI · Paper page
  81. Salman, 2009, Immunoadjuvant capacity of flagellin and mannosamine-coated poly(anhydride) nanoparticles in oral vaccination, Vaccine, 27, 4784, 10.1016/j.vaccine.2009.05.091 · DOI
  82. Stano, 2010, PPS nanoparticles as versatile delivery system to induce systemic and broad mucosal immunity after intranasal administration, Vaccine, 29, 804, 10.1016/j.vaccine.2010.11.010 · DOI
  83. Geijtenbeek, 2009, Signalling through C-type lectin receptors: shaping immune responses, Nat. Rev. Immunol., 9, 465, 10.1038/nri2569 · DOI · Paper page
  84. Bozzacco, 2007, DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes, Proc. Natl. Acad. Sci. U.S.A., 104, 1289, 10.1073/pnas.0610383104 · DOI · Paper page
  85. Cheong, 2007, Production of monoclonal antibodies that recognize the extracellular domain of mouse langerin/CD207, J. Immunol. Methods, 324, 48, 10.1016/j.jim.2007.05.001 · DOI
  86. Singh, 2009, Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation, Mol. Immunol., 47, 164, 10.1016/j.molimm.2009.09.026 · DOI
  87. Bonifaz, 2004, In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination, J. Exp. Med., 199, 815, 10.1084/jem.20032220 · DOI · Paper page
  88. Irache, 2008, Mannose-targeted systems for the delivery of therapeutics, Expert Opin. Drug Deliv., 5, 703, 10.1517/17425247.5.6.703 · DOI · Paper page
  89. Goodridge, 2009, Beta-glucan recognition by the innate immune system, Immunol. Rev., 230, 38, 10.1111/j.1600-065X.2009.00793.x · DOI · Paper page
  90. Berner, 2008, Conjugation of protein antigen to microparticulate beta-glucan from Saccharomyces cerevisiae: a new adjuvant for intradermal and oral immunizations, Appl. Microbiol. Biotechnol., 80, 1053, 10.1007/s00253-008-1618-8 · DOI
  91. Huang, 2010, Robust stimulation of humoral and cellular immune responses following vaccination with antigen-loaded beta-glucan particles, MBio, 1, 1, 10.1128/mBio.00164-10 · DOI · Paper page
  92. Schoenen, 2010, Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate, J. Immunol., 184, 2756, 10.4049/jimmunol.0904013 · DOI · Paper page
  93. Davidsen, 2005, Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6(-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses, Biochim. Biophys. Acta, 1718, 22, 10.1016/j.bbamem.2005.10.011 · DOI · Paper page
  94. Korsholm, 2007, The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes, Immunology, 121, 216, 10.1111/j.1365-2567.2007.02560.x · DOI · Paper page
  95. Franchi, 2009, Function of Nod-like receptors in microbial recognition and host defense, Immunol. Rev., 227, 106, 10.1111/j.1600-065X.2008.00734.x · DOI · Paper page
  96. Manji, 2002, PYPAF1, a PYRIN-containing Apaf1-like protein that assembles with ASC and regulates activation of NF-kappa B, J. Biol. Chem., 277, 11570, 10.1074/jbc.M112208200 · DOI · Paper page
  97. Ting, 2010, How the noninflammasome NLRs function in the innate immune system, Science, 327, 286, 10.1126/science.1184004 · DOI · Paper page
  98. Ting, 2005, CATERPILLER: a novel gene family important in immunity, cell death, and diseases, Annu. Rev. Immunol., 23, 387, 10.1146/annurev.immunol.23.021704.115616 · DOI · Paper page
  99. Ting, 2008, The NLR gene family: a standard nomenclature, Immunity, 28, 285, 10.1016/j.immuni.2008.02.005 · DOI · Paper page
  100. Tattoli, 2008, NLRX1 is a mitochondrial NOD-like receptor that amplifies NF-kappaB and JNK pathways by inducing reactive oxygen species production, EMBO Rep., 9, 293, 10.1038/sj.embor.7401161 · DOI · Paper page
  101. Aganna, 2002, Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis, Arthritis Rheum., 46, 2445, 10.1002/art.10509 · DOI · Paper page
  102. Hoffman, 2001, Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle–Wells syndrome, Nat. Genet., 29, 301, 10.1038/ng756 · DOI · Paper page
  103. Li, 2008, Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3, J. Immunol., 181, 17, 10.4049/jimmunol.181.1.17 · DOI · Paper page
  104. Tanabe, 2004, Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition, EMBO J., 23, 1587, 10.1038/sj.emboj.7600175 · DOI · Paper page
  105. Martinon, 2004, Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome, Curr. Biol., 14, 1929, 10.1016/j.cub.2004.10.027 · DOI · Paper page
  106. Jain, 2009, Well-defined and potent liposomal hepatitis B vaccines adjuvanted with lipophilic MDP derivatives, Nanomed.: Nanotechnol. Biol. Med., 5, 334, 10.1016/j.nano.2008.12.004 · doi:10.1016/j.nano.2008.12.004
  107. Sridevi, 2003, Reversal of T cell anergy in leprosy patients: in vitro presentation with Mycobacterium leprae antigens using murabutide and Trat peptide in liposomal delivery, Int. Immunopharmacol., 3, 1589, 10.1016/S1567-5769(03)00181-4 · doi:10.1016/s1567-5769(03)00181-4
  108. Hubbell, 2009, Materials engineering for immunomodulation, Nature, 462, 449, 10.1038/nature08604 · DOI · Paper page
  109. Ali, 2009, Infection-mimicking materials to program dendritic cells in situ, Nat. Mater., 8, 151, 10.1038/nmat2357 · DOI · Paper page
  110. Stern, 2009, Spatiotemporal control over molecular delivery and cellular encapsulation from electropolymerized micro- and nanopatterned surfaces, Adv. Funct. Mater., 19, 2888, 10.1002/adfm.200900307 · DOI
  111. Alving, 1992, Liposomes containing lipid A as a potent non-toxic adjuvant, Res. Immunol., 143, 197, 10.1016/S0923-2494(92)80165-H · doi:10.1016/s0923-2494(92)80165-h
  112. Jain, 2009, Well-defined and potent liposomal hepatitis B vaccines adjuvanted with lipophilic MDP derivatives, Nanomedicine, 5, 334, 10.1016/j.nano.2008.12.004 · doi:10.1016/j.nano.2008.12.004
  113. Bartenschlager, 2006, Hepatitis C virus molecular clones: from cDNA to infectious virus particles in cell culture, Curr. Opin. Microbiol., 9, 416, 10.1016/j.mib.2006.06.012 · DOI
  114. Aaltonen, 1998, A novel method to culture laryngeal human papillomavirus-positive epithelial cells produces papilloma-type cytology on collagen rafts, Eur. J. Cancer, 34, 1111, 10.1016/S0959-8049(98)00047-1 · doi:10.1016/s0959-8049(98)00047-1
  115. Kotton, 2008, Vaccination and immunization against travel-related diseases in immunocompromised hosts, Expert Rev. Vaccines, 7, 663, 10.1586/14760584.7.5.663 · DOI
  116. Naylor, 1994, Demonstration of a virulent subpopulation in a prototype live attenuated turkey rhinotracheitis vaccine, Vaccine, 12, 1225, 10.1016/0264-410X(94)90248-8 · doi:10.1016/0264-410x(94)90248-8
  117. Xiang, 2006, Pathogen recognition and development of particulate vaccines: does size matter?, Methods, 40, 1, 10.1016/j.ymeth.2006.05.016 · DOI · Paper page
  118. Beaudette, 2009, In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines, Mol. Pharm., 6, 1160, 10.1021/mp900038e · DOI
  119. Shen, 2006, Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles, Immunology, 117, 78, 10.1111/j.1365-2567.2005.02268.x · DOI · Paper page
  120. Kanchan, 2009, Memory antibody response from antigen loaded polymer particles and the effect of antigen release kinetics, Biomaterials, 30, 4763, 10.1016/j.biomaterials.2009.05.075 · DOI
  121. Howland, 2008, Antigen release kinetics in the phagosome are critical to cross-presentation efficiency, J. Immunol., 180, 1576, 10.4049/jimmunol.180.3.1576 · DOI
  122. Aguado, 1992, Controlled-release vaccines—biodegradable polylactide/polyglycolide (PL/PG) microspheres as antigen vehicles, Immunobiology, 184, 113, 10.1016/S0171-2985(11)80470-5 · DOI
  123. Espuelas, 2008, Influence of ligand valency on the targeting of immature human dendritic cells by mannosylated liposomes, Bioconjug. Chem., 19, 2385, 10.1021/bc8002524 · DOI
  124. Coombes, 1999, Biodegradable lamellar particles of poly(lactide) induce sustained immune responses to a single dose of adsorbed protein, Vaccine, 17, 2410, 10.1016/S0264-410X(99)00025-0 · doi:10.1016/s0264-410x(99)00025-0
  125. Katare, 2003, Potentiation of immune response from polymer-entrapped antigen: toward development of single dose tetanus toxoid vaccine, Drug Deliv., 10, 231, 10.1080/714044314 · doi:10.1080/714044314
  126. Yuki, 2009, Mucosal vaccines: novel advances in technology and delivery, Expert Rev. Vaccines, 8, 1083, 10.1586/erv.09.61 · DOI
  127. Neutra, 2006, Mucosal vaccines: the promise and the challenge, Nat. Rev. Immunol., 6, 148, 10.1038/nri1777 · DOI · Paper page
  128. Vajdy, 2004, Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines, Immunol. Cell Biol., 82, 617, 10.1111/j.1440-1711.2004.01288.x · DOI

Cited by

See all 176

Metadata

Authors
Demento, S. L., Siefert, A. L., Bandyopadhyay, A., Sharp, F. A., & Fahmy, T. M.
Venue
Trends in Biotechnology
Publisher
Elsevier BV
Published
2011-06
Volume
29
Issue
6
Pages
294-306
ISSN
0167-7799 (ISSN-L)
DOI
10.1016/j.tibtech.2011.02.004
OpenAlex
W2078364862
Cited by
176
References
9
FWCI
0.90
Type
journal article
Language
en
Open access
green
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.